drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor targeting CD5; CAR engagement induces MHC-independent T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity against CD5+ malignant T cells, with potential on-target effects on normal CD5+ T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting CD5. CAR engagement on CD5+ cells triggers MHC-independent T-cell activation and expansion, leading to cytokine release and perforin/granzyme-mediated cytotoxicity against CD5-expressing malignant T cells, with potential on-target effects on normal CD5+ T cells.
drug_name
CD5 CAR T-cells
nct_id_drug_ref
NCT06633341